These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23383730)

  • 21. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
    Hohlfeld R
    Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
    [No Abstract]   [Full Text] [Related]  

  • 22. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK; Butler JS; Mattingly M; Ryan M
    J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
    [No Abstract]   [Full Text] [Related]  

  • 24. Rebif offers another option for treating multiple sclerosis.
    Ryan M
    J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interferon therapy of multiple sclerosis].
    Jensen D
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 28. Contemporary immunomodulatory therapy for multiple sclerosis.
    Rudick RA
    J Neuroophthalmol; 2001 Dec; 21(4):284-91. PubMed ID: 11756861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
    Almeida L; Neves M; Cardoso E; Melo A
    J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract]   [Full Text] [Related]  

  • 31. Interferon beta treatment in relapsing-remitting multiple sclerosis. A review.
    Grigoriadis N
    Clin Neurol Neurosurg; 2002 Jul; 104(3):251-8. PubMed ID: 12127664
    [No Abstract]   [Full Text] [Related]  

  • 32. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R
    Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
    [No Abstract]   [Full Text] [Related]  

  • 33. Treat early, but treat hard: Interferon-beta dose makes a difference.
    Mikol DD
    J Neuroophthalmol; 2001 Dec; 21(4):237-9. PubMed ID: 11756850
    [No Abstract]   [Full Text] [Related]  

  • 34. Optimizing immunomodulatory therapy for MS patients: an integrated management model.
    Jeffery D; Bashir K; Buchwald L; Coyle P; Freedman M; Markowitz C; Rammohan K; Reder T; Sharief M; Wolinsky J
    J Neurol Sci; 2002 Sep; 201(1-2):89-90. PubMed ID: 12163200
    [No Abstract]   [Full Text] [Related]  

  • 35. [Ensuring the long-term effectiveness of MS treatment].
    Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16515305
    [No Abstract]   [Full Text] [Related]  

  • 36. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a.
    Tola MR; Caniatti LM; Gragnaniello D; Russo M; Stabellini N; Granieri E
    J Neurol; 2003 Jun; 250(6):768-9. PubMed ID: 12862038
    [No Abstract]   [Full Text] [Related]  

  • 37. Shortcomings in pharmacy benefit forecasting--interferon beta products.
    Rich SJ; Meyer C
    J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461
    [No Abstract]   [Full Text] [Related]  

  • 38. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.
    Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson K
    J Med Econ; 2010; 13(3):464-71. PubMed ID: 20662760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al].
    Labetouelle M
    J Fr Ophtalmol; 2001 Feb; 24(2):222. PubMed ID: 11332406
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.